[Comutagen interaction of verapamil and ribavirin].
The chromosome aberration assay in the bone marrow cells of C57BL/6 mice was used to study the cytogenetic activity of ribavirin (10, 50, 100, 200, and 400 mg/kg, p.o.) alone and in combinations with verapamil (0.25, 2.5, 5, and 10 mg/kg, p.o.). It was established that ribavirin was cytogenetically active upon single administration in a dose of 200 and 400 mg/kg, and it was also active in a dose of 50 and 100 mg/kg when administered for 5 days in combination with verapamil in a dose of 5 or 10 mg/kg and 2.5, 5, or 10 mg/kg, respectively. These results indicate that verapamil and ribavirin exhibit comutagen action.
Durnev
A D
AD
Daugel'-Dauge
N O
NO
Seredenin
S B
SB
D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects*; D001854:Bone Marrow Cells / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D002869:Chromosome Aberrations / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009153:Mutagens / Q000009:adverse effects*; D012254:Ribavirin / Q000009:adverse effects*; D014700:Verapamil / Q000009:adverse effects*
D000998:Antiviral Agents; D002121:Calcium Channel Blockers; D009153:Mutagens; D012254:Ribavirin; D014700:Verapamil